Colorectal cancer (CRC) is highly heterogeneous at the genetic and molecular level, which
has major repercussions on the efficacy of immunotherapy. A small subset of CRCs exhibit …

Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-
D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as …

How the genomic landscape of a tumor shapes and is shaped by anti-tumor immunity has
not been systematically explored. Using large-scale genomic data sets of solid tissue tumor …

Highlights•Tumor immune escape compromises the efficacy of cancer immunotherapy.•Loss
of MHC class I expression is a frequent event in cancer cells.•Three tumor phenotypes …

PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-
PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1–PD …

Colorectal cancer (CRC) exhibits differences in incidence, pathogenesis, molecular
pathways and outcome depending on the location of the tumor. This review focuses on the …

Genomic instability can initiate cancer, augment progression, and influence the overall
prognosis of the affected patient. Genomic instability arises from many different pathways …

The immunotherapeutic treatment of various cancers with an increasing number of immune
checkpoint inhibitors (ICIs) has profoundly improved the clinical management of advanced …

The immune system can recognize and attack cancer cells, especially those with a high load
of mutation-induced neoantigens. Such neoantigens are abundant in DNA mismatch repair …

High macrophage infiltration has been correlated to improved survival in colorectal cancer
(CRC). Tumor associated macrophages (TAMs) play complex roles in tumorigenesis since …